NO992106D0 - Terapeutisk anvendelse av vekstfaktor og leveringsanordning, spesielt for behandling av intimal hyperplasi - Google Patents

Terapeutisk anvendelse av vekstfaktor og leveringsanordning, spesielt for behandling av intimal hyperplasi

Info

Publication number
NO992106D0
NO992106D0 NO992106A NO992106A NO992106D0 NO 992106 D0 NO992106 D0 NO 992106D0 NO 992106 A NO992106 A NO 992106A NO 992106 A NO992106 A NO 992106A NO 992106 D0 NO992106 D0 NO 992106D0
Authority
NO
Norway
Prior art keywords
treatment
intimal hyperplasia
growth factor
delivery device
therapeutic use
Prior art date
Application number
NO992106A
Other languages
English (en)
Other versions
NO326303B1 (no
NO992106L (no
Inventor
John Francis Martin
Seppo Ylo-Herrttuala
Stephen George Edward Barker
Original Assignee
Eurogene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622852.3A external-priority patent/GB9622852D0/en
Priority claimed from GBGB9709494.0A external-priority patent/GB9709494D0/en
Priority claimed from GBGB9717791.9A external-priority patent/GB9717791D0/en
Application filed by Eurogene Ltd filed Critical Eurogene Ltd
Publication of NO992106D0 publication Critical patent/NO992106D0/no
Publication of NO992106L publication Critical patent/NO992106L/no
Publication of NO326303B1 publication Critical patent/NO326303B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
NO19992106A 1996-11-01 1999-04-30 Anvendelse av VEGF protein for behandling av intimal hyperplasi NO326303B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9622852.3A GB9622852D0 (en) 1996-11-01 1996-11-01 Treatment of intimal hyperplasma
GBGB9709494.0A GB9709494D0 (en) 1997-05-09 1997-05-09 Delivery device and method
GBGB9717791.9A GB9717791D0 (en) 1997-08-21 1997-08-21 Treatment of intimal hyperplasia
PCT/GB1997/003015 WO1998020027A2 (en) 1996-11-01 1997-11-03 Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device

Publications (3)

Publication Number Publication Date
NO992106D0 true NO992106D0 (no) 1999-04-30
NO992106L NO992106L (no) 1999-06-30
NO326303B1 NO326303B1 (no) 2008-11-03

Family

ID=27268562

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992106A NO326303B1 (no) 1996-11-01 1999-04-30 Anvendelse av VEGF protein for behandling av intimal hyperplasi

Country Status (14)

Country Link
US (1) US7320679B2 (no)
EP (2) EP0941116B1 (no)
JP (3) JP2001503755A (no)
KR (1) KR100695590B1 (no)
AT (1) ATE287271T1 (no)
AU (1) AU729420B2 (no)
CA (1) CA2270286C (no)
DE (1) DE69732304T2 (no)
ES (1) ES2235227T3 (no)
HU (1) HU223957B1 (no)
NO (1) NO326303B1 (no)
PL (1) PL189744B1 (no)
PT (1) PT941116E (no)
WO (1) WO1998020027A2 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US20080305999A1 (en) * 1996-11-01 2008-12-11 John Francis Martin Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
DE69821011T3 (de) * 1997-10-02 2009-01-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
GB9809082D0 (en) 1998-04-28 1998-06-24 Eurogene Limited Delivery device
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.
US6596699B2 (en) 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
IL145834A0 (en) * 1999-04-26 2002-07-25 Aventis Pharma Sa Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
FR2792531B1 (fr) * 1999-04-26 2003-01-31 Aventis Pharma Sa Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
JP2003509463A (ja) * 1999-09-23 2003-03-11 アン−ゴー−ジェン インコーポレーテッド 肺系のための細胞ベースの遺伝子治療
IL148674A0 (en) * 1999-11-02 2002-09-12 Genentech Inc Modulation of enos activity and therapeutic uses thereof
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
SE0000285D0 (sv) * 1999-12-07 2000-01-31 Mika Lahtinen Medical implant
AU3988401A (en) 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
GB0012997D0 (en) * 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
WO2002096469A2 (en) * 2001-05-29 2002-12-05 Ark Therapeutics Ltd. Gene delivery via a baculovirus vector
WO2003003948A1 (en) * 2001-07-06 2003-01-16 Tricardia, L.L.C. Anti-arrhythmia devices and methods of use
SE0102578L (sv) * 2001-07-20 2003-01-21 Oeyvind Reitan Förändring av en stents egenskaper för att förhindra restenos
US20060154884A1 (en) * 2003-06-18 2006-07-13 Arnd Buchwald Use of a vegf receptor gener or gene product
GB0515140D0 (en) 2005-07-22 2005-08-31 Ark Therapeutics Ltd Therapeutic device
EP1919944B1 (en) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modified vegf and pdgf with improved angiogenic properties
TWI428143B (zh) * 2006-01-18 2014-03-01 Gen Hospital Corp 增加淋巴功能之方法
US8721711B2 (en) 2007-06-20 2014-05-13 Oregon Health & Science University Graft having microporous membrane for uniform fluid infusion
WO2009079388A2 (en) * 2007-12-14 2009-06-25 Oregon Health & Science University Drug delivery cuff
DE102008002396A1 (de) 2008-06-12 2009-12-17 Biotronik Vi Patent Ag Implantierbares Wirkstoffreservoir und Vorrichtung mit einem implantierbaren Wirkstoffreservoir
CN108310396B (zh) * 2012-02-14 2022-07-15 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
WO2013135266A1 (en) 2012-03-12 2013-09-19 Gemvax As Treatment of non-small cell lung carcinoma by active immunotherapy
CA2880808C (en) 2012-08-01 2023-01-24 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
JP6431850B2 (ja) 2013-01-09 2018-11-28 ユナイテッド セラピューティクス コーポレイション プロスタサイクリンおよび間葉系幹細胞による脈管障害の処置
ES2927406T3 (es) 2016-10-24 2022-11-04 United Therapeutics Corp Potenciación de las propiedades inmunomoduladoras de las MSC mediante treprostinil
JP7791715B2 (ja) * 2019-04-05 2025-12-24 韓國セラミック技術院 Ｃｓｑ－タグを用いたタンパク質の発現及び精製方法
IT201900012537A1 (it) * 2019-07-22 2021-01-22 Milano Politecnico Dispositivo di condizionamento per condizionare un tratto esposto di un vaso sanguigno e metodo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797485A (en) * 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
JPS56122317A (en) * 1980-02-29 1981-09-25 Koken:Kk Drug transporting material and its preparation
US5326568A (en) * 1991-05-03 1994-07-05 Giampapa Vincent C Method of tissue-specific delivery
US5201728A (en) * 1991-05-03 1993-04-13 Giampapa Vincent C Subcutaneous implantable multiple-agent delivery system
US5399352A (en) * 1993-04-14 1995-03-21 Emory University Device for local drug delivery and methods for using the same
EP0702518B1 (en) * 1993-06-11 2003-04-02 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5653744A (en) * 1995-04-27 1997-08-05 Khouri Biomedical Research, Inc. Device and method for vascular anastomosis
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor

Also Published As

Publication number Publication date
DE69732304D1 (de) 2005-02-24
JP4783797B2 (ja) 2011-09-28
WO1998020027A2 (en) 1998-05-14
WO1998020027A3 (en) 1998-10-08
PT941116E (pt) 2005-05-31
AU729420B2 (en) 2001-02-01
HUP9902867A3 (en) 2001-12-28
KR20000052999A (ko) 2000-08-25
US20030225020A1 (en) 2003-12-04
HU223957B1 (hu) 2005-03-29
NO326303B1 (no) 2008-11-03
AU4790697A (en) 1998-05-29
CA2270286C (en) 2009-03-03
JP2008155036A (ja) 2008-07-10
EP0941116A2 (en) 1999-09-15
NO992106L (no) 1999-06-30
JP2012031196A (ja) 2012-02-16
DE69732304T2 (de) 2005-06-02
EP0941116B1 (en) 2005-01-19
KR100695590B1 (ko) 2007-03-14
ES2235227T3 (es) 2005-07-01
JP2001503755A (ja) 2001-03-21
EP1488761A1 (en) 2004-12-22
PL333272A1 (en) 1999-11-22
ATE287271T1 (de) 2005-02-15
CA2270286A1 (en) 1998-05-14
PL189744B1 (pl) 2005-09-30
US7320679B2 (en) 2008-01-22
HUP9902867A2 (hu) 1999-12-28
HK1108845A1 (zh) 2008-05-23

Similar Documents

Publication Publication Date Title
NO992106L (no) Terapeutisk anvendelse av vekstfaktor og leveringsanordning, spesielt for behandling av intimal hyperplasi
IL135712A0 (en) Methods for treating hypercoagulable states or acquired protein c deficiency
WO1996004955A3 (en) Polymer matrix drug delivery apparatus and method
NZ266475A (en) Use of recombinant adenovirus of animal origin in making pharmaceutical composition
SG1893G (en) Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
UA32429C2 (uk) Засіб для лікування нетримання сечі
PL309398A1 (en) Interferon containing therapeutic composition
GB9321061D0 (en) Analgestic agent and its use
HU895785D0 (en) Process for the preparation of compositions and medical preparations containing acid-resistent fibroplast growth activator for treating gastrointestinal ulcer
AU4634089A (en) Needle and therapeutic device for stimulating specific points of the body
MY164077A (en) Compositions and uses of et743 for treating cancer
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
EP0324802A4 (en) Method for the treatment of body tissues and the administration of drugs thereto
GR3022030T3 (en) Composition for treating mastitis and metritis
UA42685C2 (uk) Спосіб судинорозширювальної терапії
MXPA01011503A (es) Aplicador cutaneo con cartucho de almacenamiento de liquido.
WO2001005445A3 (en) A carbon dioxide generating device for medical treatment
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
RU95102346A (ru) Способ лечения дисциркуляторной энцефалопатии
GR3002925T3 (en) Compound active in cardiovascular therapy
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
ZA93199B (en) An apparatus for use in therapeutic and/or medical treatment.
GEP19981480B (en) Method for Treating Vertebral Column
UA36666A (uk) Спосіб лікування хронічного гастриту, асоційованого із хелікобактерною інфекцією
RU94007838A (ru) Способ лечения геморрагической лихорадки с почечным синдромом

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees